MS is inherently unpredictable. A person may appear physically stable during one evaluation but experience significant ...

Higher-dose ocrelizumab produced greater peripheral B-cell depletion than the approved 600 mg regimen in two phase 3b trials ...

Share on Pinterest Scientists are trying to find blood biomarkers that may help predict the course of disease in MS. Betsie Van der Meer/Getty Images As of 2020, about 2.8 million people globally have ...

A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab – a ...

Delayed access to insurance, high out-of-pocket costs, limited awareness of available entitlements, and the absence of ...

Socioeconomic determinants such as income, education, occupation and social support profoundly influence the course and severity of multiple sclerosis (MS). Individuals with higher socioeconomic ...

- Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment - - Phase III studies for fenebrutinib in ...

Share on Pinterest A recent study reports that starting treatment at the first signs of MS symptoms could help slow disease progression. Jennifer Blount/Getty Images A recent study finds getting ...

– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of ...

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...

Higher consumption of oily fish such as tuna and salmon or lean fish like cod and perch is associated with a reduced risk for disability progression in patients with multiple sclerosis (MS), a new ...